S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
S&P 500   3,585.62 (-1.51%)
DOW   28,725.51 (-1.71%)
QQQ   267.26 (-1.70%)
AAPL   138.20 (-3.00%)
MSFT   232.90 (-1.94%)
META   135.68 (-0.54%)
GOOGL   95.65 (-1.82%)
AMZN   113.00 (-1.57%)
TSLA   265.25 (-1.10%)
NVDA   121.39 (-0.66%)
NIO   15.77 (+1.22%)
BABA   79.99 (+1.18%)
AMD   63.36 (-1.22%)
T   15.34 (-1.22%)
MU   50.10 (+0.18%)
CGC   2.73 (-1.80%)
F   11.20 (-2.35%)
GE   61.91 (-1.31%)
DIS   94.33 (-3.20%)
AMC   6.97 (-1.83%)
PYPL   86.07 (-2.97%)
PFE   43.76 (-0.91%)
NFLX   235.44 (-1.78%)
NYSE:BHC

Bausch Health Companies - BHC Stock Forecast, Price & News

$6.89
-0.06 (-0.86%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.79
$7.25
50-Day Range
$4.58
$8.84
52-Week Range
$4.00
$29.31
Volume
5.15 million shs
Average Volume
6.79 million shs
Market Capitalization
$2.49 billion
P/E Ratio
57.42
Dividend Yield
N/A
Price Target
$10.60

Bausch Health Companies MarketRank™ Forecast

Analyst Rating
Hold
2.17 Rating Score
Upside/​Downside
53.8% Upside
$10.60 Price Target
Short Interest
Bearish
8.34% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.96
Upright™ Environmental Score
News Sentiment
0.30mentions of Bausch Health Companies in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.92%
From $3.18 to $3.75 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.85 out of 5 stars

Medical Sector

50th out of 1,093 stocks

Pharmaceutical Preparations Industry

12th out of 547 stocks

BHC stock logo

About Bausch Health Companies (NYSE:BHC) Stock

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Stock News Headlines

Why These 3 Stocks Are Off to Hot September Starts (BHC)
Let’s look at what is behind the surprise rise in these three names—and whether they can continue to pace this month’s market rally.
The One Ticker Retirement Plan Over the Shoulder Demo Now Available
Market Wizard Larry Benedict crushed the market in 2022. But he hasn’t done it with a “traditional” method… For a limited time, he’s sharing a free over-the-shoulder “demo” of his strategy in action.
Bausch Health Companies (NYSE:BHC) Trading Up 5.1%
Bausch Health, Glenmark Specialty Say Health Canada Approves RYALTRIS
126% Average Gains While Stocks Crash
Investors have lost $15 trillion so far, and it's about to get much worse. But Dr. Martin Weiss offers the solution with “Crash Profits Trades.” These could have produced average gains of 126% with NO losing trades, even with stocks tumbling! Click here to discover Crash Profit Trades. pixel
13 Stocks to Sell Now According to Billionaire Larry Robbins
Bausch Health Companies Inc
Is it Safe to Invest in Bausch Health (BHC)?
Is it Safe to Invest in Bausch Health (BHC)?
Where Bausch Health Companies Stands With Analysts
See More Headlines
Receive BHC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter.

BHC Company Calendar

Last Earnings
8/02/2021
Today
9/30/2022
Next Earnings (Estimated)
11/01/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
19,600
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.60
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+53.8%
Consensus Rating
Hold
Rating Score (0-4)
2.17
Research Coverage
6 Analysts

Profitability

Net Income
$-948,000,000.00
Pretax Margin
0.32%

Debt

Sales & Book Value

Annual Sales
$8.43 billion
Cash Flow
$8.20 per share
Book Value
($0.09) per share

Miscellaneous

Free Float
311,990,000
Market Cap
$2.49 billion
Optionable
Optionable
Beta
1.21

Key Executives

  • Mr. Thomas J. Appio (Age 60)
    CEO & Director
    Comp: $2.9M
  • Mr. Thomas G. Vadaketh (Age 59)
    Exec. VP & CFO
  • Mr. Mirza Dautbegovic
    Sr. VP & COO
  • Mr. John S. Barresi (Age 49)
    Sr. VP, Controller & Chief Accounting Officer
  • Dr. Robert F. Butz
    VP of Medical & Scientific Affairs
  • Mr. Arthur J. Shannon
    Sr. VP and Head of Investor Relations & Global Communications
  • Ms. Seana Carson (Age 50)
    Exec. VP & Gen. Counsel
  • Ms. Kathleen Fitzpatrick
    Sr. VP & Chief HR Officer
  • Dr. Tage Ramakrishna M.D. (Age 48)
    Chief Medical Officer and Pres of R&D
  • Mr. Jeff Hartness
    Sr. VP of Market Access, Commercial Operations & Gov. Affairs













BHC Stock - Frequently Asked Questions

Should I buy or sell Bausch Health Companies stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares.
View BHC analyst ratings
or view top-rated stocks.

What is Bausch Health Companies' stock price forecast for 2022?

6 brokers have issued 12 month price objectives for Bausch Health Companies' stock. Their BHC share price forecasts range from $6.00 to $15.00. On average, they expect the company's share price to reach $10.60 in the next twelve months. This suggests a possible upside of 53.8% from the stock's current price.
View analysts price targets for BHC
or view top-rated stocks among Wall Street analysts.

How have BHC shares performed in 2022?

Bausch Health Companies' stock was trading at $27.61 on January 1st, 2022. Since then, BHC shares have decreased by 75.0% and is now trading at $6.89.
View the best growth stocks for 2022 here
.

Are investors shorting Bausch Health Companies?

Bausch Health Companies saw a increase in short interest in September. As of September 15th, there was short interest totaling 29,100,000 shares, an increase of 35.8% from the August 31st total of 21,430,000 shares. Based on an average trading volume of 8,950,000 shares, the days-to-cover ratio is currently 3.3 days. Currently, 8.3% of the company's stock are short sold.
View Bausch Health Companies' Short Interest
.

When is Bausch Health Companies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our BHC earnings forecast
.

How were Bausch Health Companies' earnings last quarter?

Bausch Health Companies Inc. (NYSE:BHC) issued its quarterly earnings data on Monday, August, 2nd. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.95 by $0.02. The company earned $2.10 billion during the quarter, compared to the consensus estimate of $2.12 billion. Bausch Health Companies had a net margin of 0.52% and a negative trailing twelve-month return on equity of 9,431.58%.

What guidance has Bausch Health Companies issued on next quarter's earnings?

Bausch Health Companies issued an update on its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.05 billion-$8.22 billion, compared to the consensus revenue estimate of $8.34 billion.

What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO?

43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Bausch Health Companies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC).

What is Bausch Health Companies' stock symbol?

Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC."

How do I buy shares of Bausch Health Companies?

Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bausch Health Companies' stock price today?

One share of BHC stock can currently be purchased for approximately $6.89.

How much money does Bausch Health Companies make?

Bausch Health Companies (NYSE:BHC) has a market capitalization of $2.49 billion and generates $8.43 billion in revenue each year. The company earns $-948,000,000.00 in net income (profit) each year or $0.12 on an earnings per share basis.

How many employees does Bausch Health Companies have?

The company employs 19,600 workers across the globe.

How can I contact Bausch Health Companies?

Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The official website for the company is www.bauschhealth.com. The company can be reached via phone at (514) 744-6792, via email at ir@bauschhealth.com, or via fax at 514-744-6272.

This page (NYSE:BHC) was last updated on 9/30/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.